{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-029955","form_type":"8-K","ticker":"INSM","cik":"0001104506","company_name":"INSMED Inc","filed_at":"2024-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.302099+00:00","generated_at":"2026-06-01T04:32:08.265043+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Insmed-AstraZeneca negotiation for brensocatib in COPD/asthma expires without agreement","bullets":["AstraZeneca exercised final option for brensocatib in COPD/asthma on March 8, 2024.","Negotiation period expired June 12, 2024; no agreement reached.","Insmed retains full worldwide rights to brensocatib outside COPD/asthma.","AstraZeneca has no further rights to develop or commercialize brensocatib in any indication."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-029955","json":"https://secwatch.observer/filing/0001140361-24-029955.json","markdown":"https://secwatch.observer/filing/0001140361-24-029955.md","text":"https://secwatch.observer/filing/0001140361-24-029955.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1104506/000114036124029955/0001140361-24-029955-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1104506/000114036124029955/ef20031070_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:32:08.265043+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}